It is currently Tue Sep 02, 2014 12:08 pm

News News of Sativex

Site map of Sativex » Forum : Sativex

A cannabis derived drug which has been approved in some countries to treat muscle spasticity.

England-Wales divide looms over cannabis drug

Sativex, a cannabis-derived drug for treating muscle spasms in multiple sclerosis, could be available in Wales but blocked in England.

GW Pharmaceuticals, the British company that develops cannabis-based medicines, is facing the prospect of having its multiple sclerosis treatment blocked in England but available in Wales..... Read More - http://www.ms-uk.org/sativex
Read more : England-Wales divide looms over cannabis drug | Views : 235 | Replies : 0


FRANCE APPROVES MS TREATMENT BASED ON CANNABIS

http://bionews-tx.com/news/2014/01/13/f ... -cannabis/
France Government has announced it approval for limited use of Sativex, a cannabinoid mouth spray for treating patients suffering from M.S read the website more informations
regards
seeva
Read more : FRANCE APPROVES MS TREATMENT BASED ON CANNABIS | Views : 1666 | Replies : 0


Sativex regulatory approval in Switzerland

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has received regulatory approval for its prescription medicine Sativex(R) in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing ...
Read more : Sativex regulatory approval in Switzerland | Views : 672 | Replies : 0


Mutual recognition procedure for Sativex® in France

Mutual recognition procedure for Sativex® in France announced

GW Pharmaceuticals plc, today announced the successful closing of the European Mutual Recognition Procedure (MRP) in France for Sativex(R) oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS) and a resulting recommendation for approval by the French authorities...... Read More - http://www.ms-uk.org/sativex
Read more : Mutual recognition procedure for Sativex® in France | Views : 621 | Replies : 0


New studies reinforce efficacy, safety of Sativex

GW Pharma says new studies reinforce efficacy, safety of Sativex

GW Pharmaceuticals PLC said new test data had reinforced the efficacy and safety profile of its Sativex drug for treatment of Multiple Sclerosis spasticity..... Read More - http://www.ms-uk.org/sativex
Read more : New studies reinforce efficacy, safety of Sativex | Views : 544 | Replies : 0


US Investigational new drug application (IND) for Sativex®

US Investigational new drug application (IND) for Sativex® phase 3 clinical program for MS spasticity

GW Pharmaceuticals plc announced today that it has opened a Phase 3 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of spasticity due to Multiple Sclerosis (MS). Sativex is currently approved in 22 countries outside the U.S. as a treatment ...
Read more : US Investigational new drug application (IND) for Sativex® | Views : 945 | Replies : 0


Sativex has no long-term negative effect on MS cognition

GW Pharmaceuticals plc announced top-line results from a 12 month placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosis (MS). The study results confirm the reassuring safety profile of Sativex and provide further evidence of long-term efficacy...... Read More - http://www.securio.net/msuk/index.cfm/sativex
Read more : Sativex has no long-term negative effect on MS cognition | Views : 609 | Replies : 0


New regulatory application for MS cannabis spray Sativex®

New regulatory application for MS cannabis spray Sativex® approval in France
GW Pharmaceuticals plc announced that it has submitted an application under the European Mutual Recognition Procedure (MRP) seeking to expand the marketing authorisation for Sativex® into France for the treatment of spasticity due to Multiple Sclerosis (MS).

This new regulatory application follows a Decree signed by the French Minister of Health in June 2013, which amended national legislation in France so as to permit ...
Read more : New regulatory application for MS cannabis spray Sativex® | Views : 719 | Replies : 1


Cannabis spray Sativex® launched in Italy for MS spasticity

Cannabis spray Sativex® launched in Italy for MS spasticity

GW Pharmaceuticals & Almirall S.A. anounced today that Sativex® is now available in Italy as a prescription medicine for use in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. The launch follows receipt of full marketing authorization for Sativex® by the Italian health authorities in May. The medicine is reimbursed by the Italian ...
Read more : Cannabis spray Sativex® launched in Italy for MS spasticity | Views : 699 | Replies : 0


Sativex® commercialisation approval in Italy

GW Pharmaceuticals plc has announced that it has received commercialisation approval for its prescription medicine Sativex® in Italy. A full marketing authorization has been granted by the authorities in Italy for the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications....... Read More - http://www.ms-uk.org/index.cfm/sativex
Read more : Sativex® commercialisation approval in Italy | Views : 839 | Replies : 0


 

Login  •  Register


Statistics

Total posts 219661 • Total topics 22679 • Total members 14295


Contact us | Terms of Service